ArticleAnnals of translational medicine2023

Can ADCs broaden the treatment landscape of metastatic ER+/HER2- breast cancer resistant to CDK4/6 inhibition?

Karen Van Baelen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.